FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310691331> ?p ?o ?g. }

• W4310691331 endingPage "S21" @default.
• W4310691331 startingPage "S20" @default.
• W4310691331 abstract "<h3>Purpose</h3> Local recurrences after previous radiotherapy (RT) are increasingly being identified with increasing use of molecular imaging in biochemically recurrent prostate cancer. Salvage prostate brachytherapy (BT) is an effective and well tolerated treatment option for radiorecurrent prostate cancer. While supported by multiple prospective studies, limited comparative data exists to guide optimal patient selection and treatment technique. We sought to generate international consensus statements on the use and preferred technical considerations for salvage prostate BT. <h3>Materials and Methods</h3> International experts in salvage prostate BT were invited (n=34) to participate. A three-round modified Delphi technique was utilized, with questions focused on patient- and cancer-specific criteria, type and technique of BT, and follow-up after salvage. An a priori threshold for consensus of ≥ 75% was set, with a majority opinion being set at ≥ 50%. <h3>Results</h3> Thirty international experts agreed to participate, and the response rates were 100% (30/30), 93.3% (28/30) and 100% (30/30) for the first, second and third rounds of the survey respectively. Consensus was achieved for 56% (18 of 32) statements. Consensus was achieved in several areas of patient selection, including: 1) A minimum of 2-3 years from initial RT and consideration of salvage BT; 2) MRI and PSMA PET should be acquired prior to salvage; 3) Both a targeted and systematic prostate biopsy should be performed; 4) Salvage BT can be considered after any initial RT technique; and 5) Any Gleason Score at recurrence could be considered for salvage. Several areas did not reach consensus and were controversial: 1) Cut off for maximum T stage and PSA at time of salvage; 2) Whether ADT should be used with salvage BT (and duration); 3) Whether it was appropriate to combine local salvage with SBRT for oligometastatic disease and 4) Whether salvage BT may be repeated more than once. More than 50% of respondents preferred High Dose-Rate salvage BT, and indicated that both focal and whole gland salvage could be appropriate depending on the clinical situation. There was no single preferred dose fractionation for salvage prostate BT. <h3>Conclusions</h3> These findings will inform development of an international expert consensus statement for salvage prostate BT. Consensus was achieved on 56% of statements, though several controversial areas were identified. While our results highlight there is no single preferred approach for salvage BT, areas of controversy will be relevant for the design of future prospective studies and clinical trials of salvage BT." @default.
• W4310691331 created "2022-12-15" @default.
• W4310691331 creator A5000269137 @default.
• W4310691331 creator A5004512883 @default.
• W4310691331 creator A5005156213 @default.
• W4310691331 creator A5010337409 @default.
• W4310691331 creator A5010345728 @default.
• W4310691331 creator A5015825685 @default.
• W4310691331 creator A5015936442 @default.
• W4310691331 creator A5020453607 @default.
• W4310691331 creator A5021967618 @default.
• W4310691331 creator A5023976830 @default.
• W4310691331 creator A5027345031 @default.
• W4310691331 creator A5028818987 @default.
• W4310691331 creator A5040586351 @default.
• W4310691331 creator A5040900375 @default.
• W4310691331 creator A5041230511 @default.
• W4310691331 creator A5042728664 @default.
• W4310691331 creator A5046270690 @default.
• W4310691331 creator A5049646055 @default.
• W4310691331 creator A5050323560 @default.
• W4310691331 creator A5056079279 @default.
• W4310691331 creator A5060424758 @default.
• W4310691331 creator A5066520351 @default.
• W4310691331 creator A5076067044 @default.
• W4310691331 creator A5082021255 @default.
• W4310691331 creator A5085771294 @default.
• W4310691331 date "2022-11-01" @default.
• W4310691331 modified "2023-09-27" @default.
• W4310691331 title "PP02 Presentation Time: 9:10 AM" @default.
• W4310691331 doi "https://doi.org/10.1016/j.brachy.2022.09.014" @default.
• W4310691331 hasPublicationYear "2022" @default.
• W4310691331 type Work @default.
• W4310691331 citedByCount "0" @default.
• W4310691331 crossrefType "journal-article" @default.
• W4310691331 hasAuthorship W4310691331A5000269137 @default.
• W4310691331 hasAuthorship W4310691331A5004512883 @default.
• W4310691331 hasAuthorship W4310691331A5005156213 @default.
• W4310691331 hasAuthorship W4310691331A5010337409 @default.
• W4310691331 hasAuthorship W4310691331A5010345728 @default.
• W4310691331 hasAuthorship W4310691331A5015825685 @default.
• W4310691331 hasAuthorship W4310691331A5015936442 @default.
• W4310691331 hasAuthorship W4310691331A5020453607 @default.
• W4310691331 hasAuthorship W4310691331A5021967618 @default.
• W4310691331 hasAuthorship W4310691331A5023976830 @default.
• W4310691331 hasAuthorship W4310691331A5027345031 @default.
• W4310691331 hasAuthorship W4310691331A5028818987 @default.
• W4310691331 hasAuthorship W4310691331A5040586351 @default.
• W4310691331 hasAuthorship W4310691331A5040900375 @default.
• W4310691331 hasAuthorship W4310691331A5041230511 @default.
• W4310691331 hasAuthorship W4310691331A5042728664 @default.
• W4310691331 hasAuthorship W4310691331A5046270690 @default.
• W4310691331 hasAuthorship W4310691331A5049646055 @default.
• W4310691331 hasAuthorship W4310691331A5050323560 @default.
• W4310691331 hasAuthorship W4310691331A5056079279 @default.
• W4310691331 hasAuthorship W4310691331A5060424758 @default.
• W4310691331 hasAuthorship W4310691331A5066520351 @default.
• W4310691331 hasAuthorship W4310691331A5076067044 @default.
• W4310691331 hasAuthorship W4310691331A5082021255 @default.
• W4310691331 hasAuthorship W4310691331A5085771294 @default.
• W4310691331 hasConcept C121608353 @default.
• W4310691331 hasConcept C126322002 @default.
• W4310691331 hasConcept C141071460 @default.
• W4310691331 hasConcept C143998085 @default.
• W4310691331 hasConcept C19527891 @default.
• W4310691331 hasConcept C2776235491 @default.
• W4310691331 hasConcept C2776694085 @default.
• W4310691331 hasConcept C2777416452 @default.
• W4310691331 hasConcept C2780192828 @default.
• W4310691331 hasConcept C2780775027 @default.
• W4310691331 hasConcept C3020589411 @default.
• W4310691331 hasConcept C509974204 @default.
• W4310691331 hasConcept C71924100 @default.
• W4310691331 hasConceptScore W4310691331C121608353 @default.
• W4310691331 hasConceptScore W4310691331C126322002 @default.
• W4310691331 hasConceptScore W4310691331C141071460 @default.
• W4310691331 hasConceptScore W4310691331C143998085 @default.
• W4310691331 hasConceptScore W4310691331C19527891 @default.
• W4310691331 hasConceptScore W4310691331C2776235491 @default.
• W4310691331 hasConceptScore W4310691331C2776694085 @default.
• W4310691331 hasConceptScore W4310691331C2777416452 @default.
• W4310691331 hasConceptScore W4310691331C2780192828 @default.
• W4310691331 hasConceptScore W4310691331C2780775027 @default.
• W4310691331 hasConceptScore W4310691331C3020589411 @default.
• W4310691331 hasConceptScore W4310691331C509974204 @default.
• W4310691331 hasConceptScore W4310691331C71924100 @default.
• W4310691331 hasIssue "6" @default.
• W4310691331 hasLocation W43106913311 @default.
• W4310691331 hasOpenAccess W4310691331 @default.
• W4310691331 hasPrimaryLocation W43106913311 @default.
• W4310691331 hasRelatedWork W1993064858 @default.
• W4310691331 hasRelatedWork W2010020620 @default.
• W4310691331 hasRelatedWork W2027294118 @default.
• W4310691331 hasRelatedWork W2062703397 @default.
• W4310691331 hasRelatedWork W2138863125 @default.
• W4310691331 hasRelatedWork W2378574446 @default.
• W4310691331 hasRelatedWork W2417885433 @default.
• W4310691331 hasRelatedWork W3109924581 @default.

• next